- Expands specialty diagnostics portfolio with attractive molecular diagnostics capabilities, including infectious disease testing
- Complements leading life sciences offering with innovative sample preparation, assay and bioinformatics technologies
- Creates significant value and is expected to be immediately accretive to adjusted earnings per share after close
PR Newswire
WALTHAM, Mass. and VENLO, Netherlands, March 3, 2020